|
Compound class:
Endogenous peptide in human, mouse or rat
Comment: This is the endogenous ligand of the thrombopoietin receptor. It promotes proliferation of megakaryocytic cells, which leads to increased platelet production. Human TPO is not used therapeutically as it is associated with a risk of immunogenicity and the development of neutralizing anti-TPO antibodies [1-2]. As a result of this outcome small molecule TPO receptor agonists have been developed to mimic the platelet-promoting action of native TPO.
Species: Human
View more information in the IUPHAR Pharmacology Education Project: thrombopoietin |
| References |
|
1. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, Cohen B, Begley CG. (2002)
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood, 99 (7): 2599-602. [PMID:11895799] |
|
2. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. (2001)
Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 98 (12): 3241-8. [PMID:11719360] |
